Kanthou, C. (2011) Drug Report: lexibulin (iv infusion, cancer), YM BioSciences. Report. Drug Report . Thomson Reuters
Abstract
Lexibulin is a small-molecule tubulin-depolymerizing agent that is being developed by YM BioSciences as a vascular-disrupting agent (VDA) for the potential treatment of cancer. In vitro cell culture and in v ivo tumor models established that lexibulin has vascular-disrupting activity. Lexibulin is currently undergoing clinical development and can be administered either intravenously or orally. In two phase I clinical trials in patients with solid tumors, lexibulin induced changes in tumors that were consistent with vascular disruption and associated blood-flow modifications. Pharmacokinetics of lexibulin were favorable and generally dose- linear for both the oral and intravenous formulations. The side-effect profile of lexibulin was similar to t hat of other VDAs and included cardiovascular, respiratory and hematological toxicities. Lexibulin was also to be assessed in a phase Ib/II trial in combination with carboplatin in patients with relapsed glioblastoma multiforme and a phase II trial as monotherapy in patients with multiple myeloma. However, both trials were terminat ed, although preliminary efficacy results are available for the combination trial. At the time of publica tion, lexibulin remained listed as being in phase II development on YM BioSciences ' pipeline.
Metadata
Item Type: | Monograph |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2011 Thomson Reuters. Reproduced in accordance with the publisher's self-archiving policy. |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Oncology (Sheffield) |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 16 Oct 2015 13:04 |
Last Modified: | 16 Oct 2015 13:04 |
Published Version: | https://partnering.thomson-pharma.com/partnering/p... |
Status: | Published |
Publisher: | Thomson Reuters |
Series Name: | Drug Report |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:86822 |